红日药业(300026.SZ)：注射用甲磺酸萘莫司他获得药物临床试验批件

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) has received approval from the National Medical Products Administration for clinical trials of its injectable drug, Nirmatrelvir, which is aimed at treating acute symptoms of pancreatitis and other related conditions [1] Group 1 - The injectable Nirmatrelvir is intended to improve acute symptoms of pancreatitis and treat disseminated intravascular coagulation syndrome (DIC) [1] - The drug is also designed to prevent coagulation during blood circulation in patients with bleeding tendencies during procedures like dialysis and plasma exchange [1] - Nirmatrelvir is a novel protease inhibitor that exhibits strong and broad inhibitory effects on trypsin, complement system, coagulation-fibrinolysis system, and platelet aggregation [1]